Stryker acquiring Sage Products in $2.7 billon deal

Medical technology company Stryker plans to acquire Cary, Ill.–based Sage Products, which manufactures a host of products meant to prevent so-called “never events” in ICUs and hospitals, including hospital-acquired infections.

The all-cash transaction is valued at $2.775 billion, and is expected to close in the second quarter of 2016, pending customary closing conditions.

Founded in 1971, Sage Products is a $430-million-a-year business that makes and distributes products for oral care, skin preparation and protection, patient cleaning and hygiene, and turning and positioning of patients, as well as heel care boots.

Sage Products sales were up 13 percent in 2015.

“The company's established leadership team and innovative products that help prevent hospital-acquired conditions have driven consistent double-digit sales growth," Stryker CEO Kevin Lobo said in a release.

Sage’s portfolio of disposable products also complement Stryker products including ICU and hospital beds. The Sage acquisition goes along with Stryker’s growth strategy, which Lobo recently described as being based on a diversified sales footprint bolstered by “healthy R&D investment and a focus and disciplined M&A effort."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.